AstraZeneca's stock fell by 5.5% as investors reacted negatively to reports of merger talks with Bristol Myers Squibb, potentially creating a $400 billion pharmaceutical giant. This development highlights investor skepticism about large-scale acquisitions in the pharma sector despite potential financial gains. Additionally, Amgen disclosed a cybersecurity breach involving theft of company and patient data from third-party cloud storage systems, underscoring ongoing security challenges for healthcare firms.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





